Shares of CHYM are trading around $34.55, up approximately 9% over the trailing 30 days and near their recent 52-week high. This advance builds on a sharp August rally, when the stock climbed roughly 44% after the company reported results that comfortably exceeded expectations. Since the start of 2026, CHYM has gained more than 30%, outperforming the broader financial technology landscape.
The move marks a notable shift in sentiment. After pricing its initial public offering at $27 in June 2025 and closing its first trading day around $37, the stock later slid below its IPO price amid concerns about slowing growth. The August earnings report reframed the narrative, and Chime's market capitalization has since returned to the range of roughly $12.8 billion reported in recent coverage. I checked comparable names using Tickeron’s AI Screener to see how CHYM stacks up against peers.
Chime Financial is a San Francisco-based financial technology company, not a bank. Founded in 2012 and led by CEO Chris Britt, the company offers fee-free checking and savings accounts, debit and credit cards, early access to direct deposits, and credit-building tools through its mobile-first platform. Deposits are FDIC-insured through partner banks including The Bancorp Bank and Stride Bank.
Revenue is generated primarily from interchange fees when members use Chime-branded cards, supplemented by lending products such as MyPay and Instant Loan and the newer Chime Invest offering. The company serves roughly 10.4 million active members, with an average revenue per active member (ARPAM) of about $260. Its competitive strengths lie in a low-cost, technology-driven operating model, a large base of mainstream and underserved consumers, and improving unit economics as it expands higher-engagement products. In digital banking, it competes with incumbent institutions and listed fintech peers such as SoFi.
The primary catalyst was the second-quarter report released in early August. Revenue of $670 million represented 27% year-over-year growth, and adjusted EBITDA of $102 million pushed the adjusted EBITDA margin to 15%, up 12 percentage points from the prior-year period. The company also recorded $28 million in GAAP net income, its second straight profitable quarter, and raised full-year revenue guidance to $2.725–$2.745 billion with adjusted EBITDA of $465–$475 million.
Product momentum reinforced the results. Chime Prime, launched in April, targets members with at least $3,000 in monthly direct deposits and has generated more than double the ARPAM of the average member. Chime Invest, introduced in July, extends the platform into self-directed and managed investing. The company also announced that Allied Universal, a large U.S. employer, signed on for the Chime Workplace suite. Supporting these moves, Chime disclosed a 10% workforce reduction aimed at efficiency, a $500 million warehouse facility with Goldman Sachs, and a CFO transition. From what I see, these updates point to improving execution.
Chime enters the back half of 2026 with raised expectations. For the third quarter, management guided to revenue of $680–$690 million and adjusted EBITDA of $105–$110 million, and it now targets roughly 1.8 million net new active members for the year, above its prior goal. The next earnings report is anticipated in November 2026.
Key factors to monitor include continued growth in active members and ARPAM, adoption of Chime Prime and Chime Invest, and the ramp of credit products such as Instant Loan and the planned revolving line of credit. Investors will also watch loss rates on lending products, the impact of the restructuring on operating leverage, and the broader health of the lower- and middle-income consumer base that Chime serves. With the stock trading at a premium multiple relative to its earnings, sustaining the profitability inflection and member-monetization trajectory will be central to the valuation debate. I’m watching this closely as the story evolves.
In my own research process, I often turn to Tickeron’s AI-driven platforms to evaluate trading strategies and compare performance across different approaches. These tools help surface systematic signals that complement traditional fundamental work, especially when assessing momentum in names like CHYM. One resource I find particularly useful is the curated selection of automated strategies that highlight top-performing bots and their track records, allowing for side-by-side evaluation of holding periods and risk metrics.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Moving Average Convergence Divergence (MACD) for CHYM turned positive on October 08, 2026. Looking at past instances where CHYM's MACD turned positive, the stock continued to rise in 8 of 8 cases over the following month. The odds of a continued upward trend are 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CHYM's RSI Oscillator exited the oversold zone, 11 of 14 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on CHYM as a result. In 11 of 20 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
Following a +5.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHYM advanced for three days, in 55 of 68 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
CHYM moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CHYM crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 2 of 2 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHYM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
CHYM broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CHYM entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. CHYM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.184) is normal, around the industry mean (-1.402). P/E Ratio (5.645) is within average values for comparable stocks, (14.914). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.824). Dividend Yield (0.000) settles around the average of (0.072) among similar stocks. P/S Ratio (4.916) is also within normal values, averaging (71.128).
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHYM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PackagedSoftware